Oxytocin Treatment in Neonates and Infants With Prader-Willi Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

March 10, 2020

Primary Completion Date

October 16, 2021

Study Completion Date

March 14, 2022

Conditions
Prader-Willi Syndrome
Interventions
DRUG

OT

One group will receive OT for 4 weeks, then placebo or OT for 8 weeks

DRUG

Placebo comparator

One group will receive Placebo for 4 weeks, then Placebo or OT for 8 weeks.

Trial Locations (7)

31059

Centre de réfrence Prader-Willi, Hospital of infants, Toulouse

Unknown

Cliniques Saint Luc, Brussels

Hôpital Femme Mère Enfant, Bron

Hôpital Jeanne de Flandre, Lille

Hôpital de la Timone Enfant, Marseille

Groupe Hospitalier Necker - Enfants Malades, Paris

Klinik für Kinderheilkunde II, Essen

All Listed Sponsors
collaborator

International Clinical Trials Association

OTHER

collaborator

Epidemiological and Clinical Research Information Network

OTHER

lead

University Hospital, Toulouse

OTHER